Raynovent Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
100
- Latest Deal Type
-
2ndary - Private
- Investors
-
4
Raynovent General Information
Description
Developer of innovative drugs designed for the treatment of respiratory and metabolic diseases. The company's technology focuses on the research and development of antiviral tablets, influenza inhibitors, metabolic syndrome injections, respiratory disease therapies, liver disease treatments, and pediatric drug formulations, providing healthcare professionals with specialised pharmaceutical options intended to improve patient outcomes for viral and infectious conditions.
Contact Information
Website
www.raynovent.comCorporate Office
- Room 501, Building D
- Number 288, Shenzhou Road, Huangpu District
- Guangzhou, Guangdong 518000
- China
Corporate Office
- Room 501, Building D
- Number 288, Shenzhou Road, Huangpu District
- Guangzhou, Guangdong 518000
- China
Raynovent Timeline
Raynovent Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Secondary Transaction - Private | 20-Sep-2026 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Private | 31-Jul-2025 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 01-Dec-2022 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 15-Dec-2020 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 01-Jun-2019 | $20M | $35.8M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 26-Dec-2018 | $15.8M | $15.8M | Completed | Generating Revenue |
Raynovent Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Raynovent Patents
Raynovent Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026195049-A1 | Calcitonin and/or amylin receptor agonist and use | Pending | 21-Mar-2025 | ||
| WO-2026194855-A1 | Amylin analogue having modified structure | Pending | 17-Mar-2025 | ||
| WO-2026119226-A1 | Oral solid pharmaceutical composition, preparation method therefor, and use thereof | Pending | 06-Dec-2024 | ||
| WO-2026119227-A1 | Pyrimidine derivative-containing pharmaceutical composition and use thereof | Pending | 06-Dec-2024 | ||
| WO-2025237212-A1 | Pyrimidine derivative meglumine salt and crystal forms thereof | Pending | 11-May-2024 |
Raynovent Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Raynovent Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Wanlian Securities Co. | Asset Manager | Minority | ||
| BoCom International | Asset Manager | Minority | ||
| Guangdong Zhongsheng Pharmaceutical | Corporation | Minority | ||
| BioTrack Capital | Venture Capital | Minority |
Raynovent FAQs
-
When was Raynovent founded?
Raynovent was founded in 2018.
-
Where is Raynovent headquartered?
Raynovent is headquartered in Guangzhou, China.
-
What is the size of Raynovent?
Raynovent has 100 total employees.
-
What industry is Raynovent in?
Raynovent’s primary industry is Drug Discovery.
-
Is Raynovent a private or public company?
Raynovent is a Private company.
-
What is Raynovent’s current revenue?
The current revenue for Raynovent is .
-
How much funding has Raynovent raised over time?
Raynovent has raised $130M.
-
Who are Raynovent’s investors?
Wanlian Securities Co., BoCom International, Guangdong Zhongsheng Pharmaceutical, and BioTrack Capital have invested in Raynovent.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
